TY - JOUR
T1 - Microbiomes in Acne Vulgaris and Their Susceptibility to Antibiotics in Indonesia
T2 - A Systematic Review and Meta-Analysis
AU - Legiawati, Lili
AU - Halim, Paulus Anthony
AU - Fitriani, Magna
AU - Hikmahrachim, Hardya Gustada
AU - Lim, Henry W.
N1 - Funding Information:
This work was funded by the Directorate of Research and Development, Universitas Indonesia under Hibah Puti 2022 (Grant No. NKB-751/UN2.RST/HKP.05.00/2022).
Funding Information:
The authors would like to thank the Directorate of Research and Development at Universitas Indonesia for providing funding for this work.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Hot and humid countries such as Indonesia have a higher prevalence of acne vulgaris (AV). The activity of skin microbes, not only Cutibacterium acnes, contribute to the formation of AV. Topical and oral antibiotics are routinely prescribed to treat AV. As antimicrobial resistance rates increase globally, there are concerns about decreased efficacy. This study intends to systematically evaluate the microbiomes isolated from AV lesions and their antibiotics susceptibility in Indonesia. The data were retrieved through PubMed, EMBASE, Google Scholar, and ScienceDirect searches for articles published until July 2022 using three multiword searches. Sixteen studies published between 2001 and 2022 were identified from which the data were pooled using a random effects model. The pooled prevalence estimates demonstrated that C. acnes, Staphylococcus epidermidis, and Staphylococcus aureus were the three common microbes associated with AV in Indonesia. Tetracyclines had lower resistance rates compared to those of macrolides and clindamycin, with C. acnes showing a resistance rate that is as high as 60.1% against macrolides. C. acnes resistance against minocycline showed an increasing trend, whereas the resistances to doxycycline, clindamycin, and macrolides stagnated. The high resistance prevalence and trends signify a public health concern. The results of this study call for the development of antibiotic stewardship programs in Indonesia, which may lead to improved acne outcomes.
AB - Hot and humid countries such as Indonesia have a higher prevalence of acne vulgaris (AV). The activity of skin microbes, not only Cutibacterium acnes, contribute to the formation of AV. Topical and oral antibiotics are routinely prescribed to treat AV. As antimicrobial resistance rates increase globally, there are concerns about decreased efficacy. This study intends to systematically evaluate the microbiomes isolated from AV lesions and their antibiotics susceptibility in Indonesia. The data were retrieved through PubMed, EMBASE, Google Scholar, and ScienceDirect searches for articles published until July 2022 using three multiword searches. Sixteen studies published between 2001 and 2022 were identified from which the data were pooled using a random effects model. The pooled prevalence estimates demonstrated that C. acnes, Staphylococcus epidermidis, and Staphylococcus aureus were the three common microbes associated with AV in Indonesia. Tetracyclines had lower resistance rates compared to those of macrolides and clindamycin, with C. acnes showing a resistance rate that is as high as 60.1% against macrolides. C. acnes resistance against minocycline showed an increasing trend, whereas the resistances to doxycycline, clindamycin, and macrolides stagnated. The high resistance prevalence and trends signify a public health concern. The results of this study call for the development of antibiotic stewardship programs in Indonesia, which may lead to improved acne outcomes.
KW - acne vulgaris
KW - antibiotic resistance
KW - clindamycin
KW - Cutibacterium acnes
KW - Indonesia
KW - macrolides
KW - Staphylococcus aureus
KW - Staphylococcus epidermidis
KW - tetracyclines
UR - http://www.scopus.com/inward/record.url?scp=85146759010&partnerID=8YFLogxK
U2 - 10.3390/antibiotics12010145
DO - 10.3390/antibiotics12010145
M3 - Review article
AN - SCOPUS:85146759010
SN - 2079-6382
VL - 12
JO - Antibiotics
JF - Antibiotics
IS - 1
M1 - 145
ER -
